FORM 6-K
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
dated May 2, 2019
Commission File Number 0-51504
GENETIC TECHNOLOGIES LIMITED
(Exact Name as Specified in its Charter)
N/A
(Translation of Registrants Name)
60-66 Hanover Street
Fitzroy
Victoria 3065 Australia
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes o No x
If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: May 2, 2019
|
GENETIC TECHNOLOGIES LIMITED | |
|
| |
|
| |
|
By: |
/s/ Paul Viney |
|
Name: |
Paul Viney |
|
Title: |
Company Secretary |
ASX ANNOUNCEMENT
2 May 2019
Genetic Technologies (ASX: GTG; Nasdaq: GENE)
Melbourne, Australia; 2 May 2019: Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) announces that it has received a letter from the Nasdaq Stock Market dated 29 April 2019 advising that the Companys reported stockholders equity is less than the minimum specified amount of US$2,500,000 as at 31 December 2018 and that Nasdaq believes the Company does not meet the alternatives of market value of listed securities or net income from continuing operations and as such no longer complies with a Nasdaq Marketplace Listing Rule (Listing Rule, or Rules).
Under the Rules, the Company has 45 calendar days to submit a plan to regain compliance and if the Plan is accepted, Nasdaq can grant an extension of up to 180 days from 29 April 2019 to evidence compliance.
The Company confirms it will be submitting the required Plan to Nasdaq within this timetable.
This deficiency notice does not immediately affect GTGs Nasdaq listing.
These Rules only apply to the Companys shares trading on The Nasdaq Capital Market and not the Companys shares trading on the Australian Securities Exchange, the Companys home exchange.
FOR FURTHER INFORMATION PLEASE CONTACT
Paul Viney
Company Secretary
Genetic Technologies Limited
+ 61 438072616
About Genetic Technologies Limited
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Companys lead product, BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. For more information, please visit www.brevagenplus.com and www.phenogensciences.com.
Genetic Technologies is developing a pipeline of risk assessment products including a novel colorectal cancer (CRC) test. For more information, please visit www.gtgcorporate.com
Safe Harbor Statement
Any statements in this press release that relate to the Companys expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Companys actual results may differ materially from expected results. Additional risks associated with Genetic Technologies business can be found in its periodic filings with the SEC.